CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
REVENUES:
Net product revenues	$ 298,576,000	$ 249,023,000	$ 533,933,000	$ 450,335,000
Collaborative agreement revenues		342,000	233,000	718,000
Royalty, license and other revenues	1,555,000	770,000	2,701,000	2,002,000
Total revenues	300,131,000	250,135,000	536,867,000	453,055,000
OPERATING EXPENSES:
Cost of sales	51,617,000	38,063,000	94,735,000	69,061,000
Research and development	167,039,000	157,901,000	325,832,000	299,975,000
Selling, general and administrative	109,577,000	101,514,000	214,877,000	194,320,000
Intangible asset amortization and contingent consideration	(54,414,000)	16,945,000	(43,972,000)	19,847,000
Impairment of intangible assets	599,118,000	0	599,118,000	0
Total operating expenses	872,937,000	314,423,000	1,190,590,000	583,203,000
LOSS FROM OPERATIONS	(572,806,000)	(64,288,000)	(653,723,000)	(130,148,000)
Equity in the loss of BioMarin/Genzyme LLC	(135,000)	(203,000)	(270,000)	(353,000)
Interest income	1,357,000	1,023,000	2,928,000	1,706,000
Interest expense	(9,944,000)	(10,002,000)	(19,787,000)	(19,464,000)
Debt conversion expense				(163,000)
Other expense	(1,417,000)	(9,073,000)	(1,219,000)	(8,824,000)
LOSS BEFORE INCOME TAXES	(582,945,000)	(82,543,000)	(672,071,000)	(157,246,000)
Benefit from income taxes	(159,385,000)	(554,000)	(163,369,000)	(7,756,000)
NET LOSS	$ (423,560,000)	$ (81,989,000)	$ (508,702,000)	$ (149,490,000)
NET LOSS PER SHARE, BASIC AND DILUTED	$ (2.61)	$ (0.51)	$ (3.14)	$ (0.94)
Weighted average common shares outstanding, basic and diluted	162,587	160,406	162,067	159,017
COMPREHENSIVE LOSS	$ (419,079,000)	$ (93,347,000)	$ (525,207,000)	$ (144,495,000)